PHARMACY

Hospira gets FDA nod for generic Merrem

BY Allison Cerra

LAKE FOREST, Ill. The Food and Drug Administration has approved a generic, injectable antibiotic.

Hospira’s meropenem for injection will be available in 500 mg and 1 g vials, the drug maker announced. It is a generic version of AstraZeneca’s Merrem, a beta-lactam antibiotic. Meropenem represents the first U.S. drug launch from Hospira’s recent acquisition of the generic injectables business of Orchid Chemicals and Pharmaceuticals.

Sales of Merrem totaled about $200 million in 2009.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

A1c readings may not be accurate for some ethnic groups, study finds

BY Alaric DeArment

NEW YORK The hemoglobin A1c test may not provide accurate results for elderly Asians, according to published reports about a new study.

 

The American Diabetes Association said the test works when doctors use an A1c reading of 6.5% to indicate diabetes, but the study, conducted in Singapore, found that the cutoff often misses the disease in older Asians. The study was conducted on participants between the ages of 20 and 93 years.

 

 

The study’s findings were scheduled to be presented Sunday at the Endocrine Society’s annual meeting in San Diego, according to the reports.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Valeant, Biovail to merge

BY Alaric DeArment

TORONTO U.S. drug maker Valeant and Canadian drug maker Biovail will merge, the two companies said Monday.

The combined company will carry the name Valeant Pharmaceuticals International but will have its headquarters in Mississauga, Ontario. Valeant is currently based in Aliso Viejo, Calif.

Under the agreement, Valeant stockholders will receive $16.77 per share immediately before the merger’s closing and, after its closing, 1.78 shares of Biovail stock for every share of Valeant stock they own. After the merger closes, Biovail shareholders will own around 50.5% and Valeant shareholders will own 49.5% of the combined company.

Biovail is known mostly for such specialty drugs as the antidepressant Wellbutrin XL (bupropion), while Valeant’s range of branded and branded generic drugs include the acne treatment Acanya Gel (clindamycin phosphate and benzoyl peroxide).

Valeant CEO J. Michael Pearson will reside in Barbados as the new CEO, while Biovail CEO Bill Wells will be nonexecutive chairman. The company’s 11-member board of directors will include five representatives from Biovail, five from Valeant and one independent Canadian resident director.

“This compelling combination will create tremendous value for stockholders of both companies as our business benefits from cost savings, greater scale, efficiencies from extending Biovail’s corporate structure and enhanced financial strength and flexibility,” Pearson said.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?